Dr Kadri Seppa

  • Research Associate
Dr Kadri Seppa

Connect

About

Biography:

Kadri obtained her doctoral degree in Neuroscience in 2021 from University of Tartu, Estonia. Her thesis focused on the development and evaluation of novel neuroprotective strategies using a rat model of Wolfram syndrome (WS). Kadri’s work in Plaas’ lab contributed to the field of Wolfram Syndrome research by (i) validating Wfs1 KO rat as a Wolfram syndrome animal model and (ii) by using the Wolfram syndrome animal model they found that liraglutide treatment could be a promising treatment strategy for Wolfram syndrome patients. Inspired by their preclinical studies, a liraglutide clinical trial has been initiated at the University of Washington, and further investigations will clarify the effect of liraglutide in Wolfram syndrome patients.

Research Interests:

Toxic injury leads to global transcriptional downregulation. The Sawarkar lab has generated mouse strains lacking specific domains of proteins that play a role in global downregulation of transcription. Kadri has joined the Sawarkar lab as a postdoc to study how these mice are sensitive to toxic insults.

Publications

Selected publications

Wfs1- deficient rats develop primary symptoms of Wolfram syndrome: insulin-dependent diabetes, optic nerve atrophy and medullary degeneration Plaas M, Seppa K, Reimets R, Jagomäe T, Toots M, Koppel T, Vallisoo T, Nigul M, Heinla I, Meier R, Kaasik A, Piirsoo A, Hickey MA, Terasmaa A, Vasar E Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome Toots M, Seppa K, Jagomäe T, Koppel T, Pallase M, Heinla I, Terasmaa A, Plaas M, Vasar E GLP-1 receptor agonist liraglutide has a neuroprotective effect on an aged rat model of Wolfram syndrome Seppa K, Toots M, Reimets R, Jagomäe T, Koppel T, Pallase M, Hasselholt S, Krogsbæk Mikkelsen M, Randel Nyengaard J, Vasar E, Terasmaa A, Plaas M Liraglutide, 7,8-DHF and their co-treatment prevents loss of vision and cognitive decline in a Wolfram syndrome rat model Seppa K, Jagomäe T, Kukker KG, Reimets R, Pastak M, Vasar E, Terasmaa A, Plaas M Early Intervention and Lifelong Treatment with GLP1 Receptor Agonist Liraglutide in a Wolfram Syndrome Rat Model with an Emphasis on Visual Neurodegeneration, Sensorineural Hearing Loss and Diabetic Phenotype Jagomäe T; Seppa K; Reimets R; Pastak M; Plaas M; Hickey MA; Kukker KG; Moons L; De Groef L; Vasar E; Kaasik A; Terasmaa A; Plaas M The Expression of RAAS Key Receptors, Agtr2 and Bdkrb1, Is Downregulated at an Early Stage in a Rat Model of Wolfram Syndrome Punapart, M.; Seppa, K.; Jagomäe, T.; Liiv, M.; Reimets, R.; Kirillov, S.; Kaasik, A.; Moons, L.; De Groef, L.; Terasmaa, A.; Vasar, E.; Plaas, M